87
Challenger brands repositioned since 2017, across consumer, beverage, beauty, fintech, and culture.
The agency that breaks the rules your category still believes in.
Brand work built to be remembered.
Not built to be approved.
A 14-person strategy studio. 87 challenger brands repositioned since 2017. Founded by four former Wieden+Kennedy and Pentagram strategists. Every project led by a partner.
87 brands repositioned since 2017 · 14 people · 4 founding partners
The diagnosis
The problem other agencies won't name out loud.
Most brand work is forgettable because it is built to survive a committee. It is approved by the room, then ignored by the market. The deck is consensus. The work is safe. The recall lift, six months later, is rounding to zero.
We have read the strategy documents of forty challenger brands that hired a "creative partner" last year. Thirty-six of them could swap their agency of record into a competitor's name and the work would not change. That is the disease.
The Amoral Autopsy is a paid 90-minute diagnostic designed to find the position your category is too polite to claim — and to tell you, on the record, whether we are the right studio to take it to market. The output is a written verdict, not a pitch deck.
By the numbers
Receipts, not adjectives.
3.4×
Average lift in unaided brand recall within six months of relaunch.
11d
Average strategy engagement close — against a 67-day Big Agency benchmark (Ad Age, 2023).
$412M
Combined disclosed acquisition value across three portfolio companies sold in 2023.
Average client tenure: 2.8 years — four times the industry average reported by RSW/US Agency Search in 2023. Referral rate in 2023: 92%.
Three deals, three acquirers, one studio
The case for a position the category hadn't named.
A deal book, not a portfolio gallery. Each row reads the same way: the brief that landed, the strategic move we made, the outcome the market returned.
01
Glow Bar
Reposition a single-location LED facial studio into the first at-home device brand for the post-chemical-peel consumer.
A "clinical-grade, no clinic" positioning and a packaging system engineered for the bathroom shelf, not the vanity case.
Acquired by
Unilever
2023
02
Rook Coffee
Pull a regional roaster out of the "local favorite" cohort and into the conversation next to the specialty nationals.
A "single-origin, single-decision" brand architecture and a wholesale strategy that traded grocery shelf-share for independent cafe density.
Acquired by
JAB Holdings
2023
03
Fieldlab
Translate a clinician-only skincare line into a consumer narrative without surrendering the medical credibility.
A "prescription-grade, never prescribed" platform and a DTC launch sequencing that kept the dermatologist channel intact through the acquisition.
Acquired by
Coty
2023
The Autopsy
Ninety minutes. One written verdict. Zero pitch decks.
A paid diagnostic for challenger brand founders who suspect their current positioning is the bottleneck. The output is yours whether or not you ever hire us.
-
01
The diagnostic
We audit your current positioning, your last three campaign briefs, your category's white space, and the seven competitors we think you are confusing yourself with. You send the documents; we send back a 14-page diagnostic dossier before the call.
-
02
The positioning verdict
Ninety minutes with one of the four founding partners. We name the position your category has been too polite to claim, the line you should be drawing, and the line you should be willing to lose customers on. A written verdict is delivered within five business days.
-
03
The 90-day activation roadmap
If you want to move together, the verdict becomes the brief for a 90-day activation sprint: naming, identity system, launch creative, and the paid media architecture. Flat fee. Published line-item pricing. No markups on production, freelance, or media.
The thesis
“Permissionless brands don't wait for the category to bless them. They take the position, they absorb the criticism, and they outlast the agencies that were too nervous to recommend it. Our job is to find the line, and to tell the founder whether they have the nerve to cross it.”
Mara Velázquez, founding partner — formerly Wieden+Kennedy
Read the 140,000-read essay →